Halozyme Therapeutics (HALO) Tops Q1 EPS by 3c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $68.99 --0%
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
JFIN, KEQU, LASE, More
EPS Growth %: +17.5%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
JFIN, KEQU, LASE, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $31.43 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $115-125 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
- Ennis (EBF) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
